Developer docs
API playgroundTry for free, no card

Search company profiles

Octant Bio

Full company profile

uuid00008lx

Namestring
Octant Bio
Legal namestring
Octant, Inc.
Websiteurl
octant.bio
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Octant Bio, Inc. is a clinical-stage biotechnology company founded in 2017 and headquartered in Emeryville, California, that engineers small-molecule therapeutics against complex cellular mechanisms of disease using an integrated discovery platform. The company's core product, the Octant Navigator, combines three interlocking modules — Generative Biology (RNA-barcoded mammalian synthetic biology toolkits that build cellular sensors for signaling, trafficking, stability, and interaction pathways), Generative Chemistry (nano-scale automated acoustic synthesis producing thousands of analogs per cycle), and Generative AI/ML — into a closed weekly Design-Build-Test-Learn loop augmented by Hypatia robotic automation and Deep Mutational Scanning datasets that map every amino-acid variant of a target protein. The company's internal pipeline spans rare genetic disease (lead clinical asset OCT-980, an oral small-molecule corrector for rhodopsin-associated autosomal dominant retinitis pigmentosa, with Phase 1a healthy-volunteer dosing initiated in Q1 2026 under NCT07408232), Fabry disease, undisclosed neurodegeneration, p53-mutant cancers, HPV-induced cancers (with the Gates Foundation), MC4R metabolism, and undisclosed immunology targets. Its value proposition centers on drugging multi-mutation, mechanism-driven diseases that traditional single-target binding approaches have failed to address.

Octant's business model is pre-commercial and predicated on three funding pillars. Venture equity financing has totaled approximately $115M across a 2017 seed, a $30M Series A led by Andreessen Horowitz in May 2020, and an $80M Series B led by Catalio Capital Management in April 2022 with Bristol Myers Squibb participation. Strategic pharma research collaborations — most notably with Bristol Myers Squibb (initial 2022 deal, renewed November 12, 2025 for neurodegenerative diseases) — provide research funding, milestone payments, and potential downstream royalties tied to partnered programs. Non-dilutive grant funding supplements this with $4.9M from the Gates Foundation (HPV-Driven Cancer Therapeutics Program, June 11, 2025) and ARPA-H Collaborative AI Initiative funding (October 23, 2024), plus a Foundation Fighting Blindness clinical collaboration (April 2026). The company is privately held by Andreessen Horowitz, Catalio Capital Management, Bristol Myers Squibb, and a syndicate including 50Y, Allen, 8VC, NanoDimension, SV Angel, Refactor, Ulu Ventures, and Lux Capital.

Go-to-market is structured as an enterprise pharma partnership motion: high-touch business development secures multi-year research collaborations and co-development agreements, supplemented by visibility at major investor and scientific conferences (Morgan Stanley, Goldman Sachs, RBC, Canaccord Genuity, Stanford Drug Discovery Symposium, Mutational Scanning Symposium) and a science-content and apprenticeship-driven employer brand that supports talent acquisition. Pricing is not publicly disclosed; commercial value is realized through deal economics with pharma partners and future clinical-pipeline milestones rather than unit sales.

Short descriptiontext

Octant Bio is a clinical-stage biotechnology company developing the Octant Navigator—an integrated Generative Biology, Chemistry, and AI drug-discovery platform targeting protein misfolding diseases—with lead asset OCT-980 in Phase 1 for RHO-adRP retinitis pigmentosa.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery platform, small molecule therapeutics, synthetic biology drug discovery, protein misfolding correctors, generative AI drug discovery
Industry1 code
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Drug Discovery Platform / Biopharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Strategic pharma research collaborations
TypeLicensing Royalties
Description

Research collaboration agreements with large pharmaceutical partners such as Bristol Myers Squibb (e.g., 2022 collaboration; November 12, 2025 collaboration to discover novel small molecules for neurodegenerative diseases). Typically involve upfront/research funding, milestone payments, and potential downstream royalties or licensing economics tied to partnered programs.

businesswire.com
2Venture equity financing
TypeSubscription Recurring
Description

Series B financing of $80M led by Catalio Capital Management in April 2022 with participation from Bristol Myers Squibb and other investors (Andreessen Horowitz, 50Y, Allen, 8VC, NanoDimension, SV Angel, Refactor, Ulu, Lux). Pre-revenue therapeutics company; primary funding mechanism to date.

businesswire.com
3Non-dilutive grant funding
TypeManaged Services
Description

Targeted grant funding supporting specific programs — e.g., $4.9M grant from the Gates Foundation to launch the HPV-Driven Cancer Therapeutics Program (June 11, 2025), and ARPA-H funding for a Collaborative AI Initiative to advance drug discovery and prevent side effects (October 23, 2024).

octant.bio
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1Quote-based / Not publicly disclosed — pre-commercial therapeutics pipeline with pharma research collaborations
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing; commercial value derived from research collaborations with pharma (e.g., Bristol Myers Squibb) and grant funding.

octant.bio
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Octant Navigator
Description

Proprietary next-generation drug discovery platform that integrates Generative Biology, Generative Chemistry, and Generative AI for design, build, test, learn iterations across chemistry and biology.

octant.bio
Core offering1 text field

Octant Bio operates the Octant Navigator, an integrated drug-discovery platform that combines Generative Biology (RNA-barcoded mammalian synthetic biology cell sensors), Generative Chemistry (nano-scale automated synthesis), and Generative AI in a weekly Design-Build-Test-Learn cycle to engineer small molecule drugs that modulate cellular mechanisms of disease. The company applies Deep Mutational Scanning to map every amino-acid variant of target proteins and currently sells its discovery capabilities via research collaborations with pharmaceutical partners (e.g., Bristol Myers Squibb), non-dilutive grants (Gates Foundation, ARPA-H), and an internal clinical pipeline led by OCT-980 (an oral small molecule corrector for RHO-adRP retinitis pigmentosa now in Phase 1a).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Iteratively built and screened 250,000+ custom compounds direct-to-biology in the RHO-adRP program, yielding leads that rescue the most prevalent clinically-relevant rhodopsin mutations, are orally bioavailable, and cross the blood-retinal barrier.
+3 more records
Product overview1 text field

Octant Bio offers a single integrated drug-discovery platform — the Octant Navigator — composed of three interlocking modules (Generative Biology, Generative Chemistry, and Generative AI) plus platform capabilities such as Deep Mutational Scanning (DMS), HT-SAR direct-to-biology screening, and the Hypatia robotic drug hunter, that together drive iterative weekly design–build–test–learn cycles on cellular mechanisms. Internal programs include the lead clinical candidate OCT-980 (an oral small-molecule corrector for RHO-associated autosomal dominant retinitis pigmentosa, Phase 1a initiated Q1 2026), along with discovery programs in Fabry disease, undisclosed neurodegeneration, p53-mutant cancers, HPV-induced cancers (Gates Foundation collaboration), MC4R metabolism, and undisclosed targets.

Product and service3 records
1Octant Navigator
CategoryDrug discovery platform / proprietary technology
Description

Next-generation drug discovery platform integrating Generative Biology, Generative Chemistry, and Generative AI in iterative design–build–test–learn loops to engineer small molecules that modulate cellular mechanisms driving disease, rather than only binding isolated target proteins.

2OCT-980
CategoryTherapeutic drug candidate
Description

First-in-disease oral small molecule corrector designed to correct protein misfolding caused by rhodopsin (RHO) gene mutations, the root cause of RHO-associated autosomal dominant retinitis pigmentosa (adRP). In Phase 1a clinical testing as of Q1 2026 with an integrated Phase 1/2 study planned.

3Pharma research collaboration and co-development services
CategoryResearch collaboration services
Description

Strategic research collaboration agreements with large pharmaceutical partners (notably Bristol Myers Squibb, originally announced 2022 and expanded November 12, 2025 for neurodegenerative diseases) that apply the Octant Navigator platform to discover novel small molecules, typically involving upfront/research funding, milestone payments, and potential downstream royalties or licensing economics.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

Collaboration announced April 21–22, 2026 to expand the Uni-Rare Natural History Study with a new RHO cohort, supporting the OCT-980 / RHO-adRP program and broader understanding of rhodopsin mutation disease progression.

2Bristol Myers Squibb
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

Research collaboration announced November 12, 2025 to discover novel small molecules for neurodegenerative diseases. Builds on the original 2022 Octant–BMS drug-discovery partnership and joint work presented at Stanford Drug Discovery Symposium 2024 on a Deep Mutational Scan of TYK2.

octant.bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-11
Description

Partner on Octant's HPV-induced cancers program (Hit ID stage in pipeline) and funder via a $4.9M grant awarded June 11, 2025 to launch the HPV-Driven Cancer Therapeutics Program.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-12-10
Description

Established a Bay Area coronavirus test processing facility in December 2020 leveraging Octant's SwabSeq technology; partnership was a non-pharma operational collaboration during the COVID-19 pandemic.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Insitro is a clinical-stage AI/ML-driven drug discovery company combining induced pluripotent stem cell biology, high-throughput genetics, and machine learning to engineer small molecule and genetic medicines. Highly comparable to Octant's Navigator approach of integrating high-throughput biology, chemistry, and ML in iterative discovery loops.

TypeBroad incumbent
Description

Ginkgo Bioworks operates a broad horizontal synthetic biology and cell programming platform serving applications from biomanufacturing to biosecurity (NYSE: DNA). Ginkgo CEO Jason Kelly sits on Octant's board, and the companies share an Emeryville-Bay Area cluster and synthetic biology heritage.

TypeDirect peer
Description

Schrödinger combines physics-based computational chemistry, ML, and a co-discovery model with pharma partners to develop small molecule therapeutics. Directly comparable to Octant's Generative Chemistry and Generative AI capabilities and its pharma-partnered business model.

TypeEmerging player
Description

Atomwise applies deep learning to structure-based small molecule design and has multiple pharma partnerships. Comparable to Octant on AI-driven small molecule discovery but smaller scale and less integrated wet-lab automation.

TypeDirect peer
Description

Exscientia is an AI-native pharma using generative design and automated chemistry to advance small molecule candidates, with multiple clinical-stage programs and major pharma partnerships. Comparable to Octant as a direct AI/chemistry platform competitor.

TypeDirect peer
Description

Recursion operates one of the largest AI-driven biology and chemistry platforms, using high-throughput automated wet-lab experiments and ML to discover small molecules across multiple therapeutic areas with several clinical-stage assets. Directly comparable to Octant on platform model, scale, and clinical-stage status.

TypeDirect peer
Description

Relay Therapeutics combines computational methods with structural biology and chemistry to design precision medicines against validated targets, with multiple clinical-stage assets. SAB member Mark Murcko is a Relay founder and the platform emphasis on motion-based drug design overlaps with Octant's mechanism-based cellular screening.

8Isomorphic Labs
TypeEmerging player
Description

Isomorphic Labs is Alphabet/DeepMind's commercial AI drug discovery entity building an integrated computational biology and chemistry platform. Comparable to Octant as an AI-native discovery platform with pharma partnerships (Novartis, Lilly) but operating at vastly greater capital scale.

TypeEmerging player
Description

Dewpoint develops small molecule drugs targeting biomolecular condensates, with SAB founder Mark Murcko. Partial overlap with Octant on mechanism-based discovery and on shared scientific leadership network.

TypeDirect peer
Description

Eikon uses live-cell high-throughput imaging combined with AI/ML to track protein dynamics in living cells for drug discovery. Comparable to Octant on the premise of generating large-scale biological datasets with ML to discover mechanistically novel small molecules.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Octant Bio

Drug Discovery Platform / Biopharmaceuticalsoctant.bio

Octant Bio is a clinical-stage biotechnology company developing the Octant Navigator—an integrated Generative Biology, Chemistry, and AI drug-discovery platform targeting protein misfolding diseases—with lead asset OCT-980 in Phase 1 for RHO-adRP retinitis pigmentosa.

What Octant Bio does

Octant Bio, Inc. is a clinical-stage biotechnology company founded in 2017 and headquartered in Emeryville, California, that engineers small-molecule therapeutics against complex cellular mechanisms of disease using an integrated discovery platform. The company's core product, the Octant Navigator, combines three interlocking modules — Generative Biology (RNA-barcoded mammalian synthetic biology toolkits that build cellular sensors for signaling, trafficking, stability, and interaction pathways), Generative Chemistry (nano-scale automated acoustic synthesis producing thousands of analogs per cycle), and Generative AI/ML — into a closed weekly Design-Build-Test-Learn loop augmented by Hypatia robotic automation and Deep Mutational Scanning datasets that map every amino-acid variant of a target protein. The company's internal pipeline spans rare genetic disease (lead clinical asset OCT-980, an oral small-molecule corrector for rhodopsin-associated autosomal dominant retinitis pigmentosa, with Phase 1a healthy-volunteer dosing initiated in Q1 2026 under NCT07408232), Fabry disease, undisclosed neurodegeneration, p53-mutant cancers, HPV-induced cancers (with the Gates Foundation), MC4R metabolism, and undisclosed immunology targets. Its value proposition centers on drugging multi-mutation, mechanism-driven diseases that traditional single-target binding approaches have failed to address.

Octant's business model is pre-commercial and predicated on three funding pillars. Venture equity financing has totaled approximately $115M across a 2017 seed, a $30M Series A led by Andreessen Horowitz in May 2020, and an $80M Series B led by Catalio Capital Management in April 2022 with Bristol Myers Squibb participation. Strategic pharma research collaborations — most notably with Bristol Myers Squibb (initial 2022 deal, renewed November 12, 2025 for neurodegenerative diseases) — provide research funding, milestone payments, and potential downstream royalties tied to partnered programs. Non-dilutive grant funding supplements this with $4.9M from the Gates Foundation (HPV-Driven Cancer Therapeutics Program, June 11, 2025) and ARPA-H Collaborative AI Initiative funding (October 23, 2024), plus a Foundation Fighting Blindness clinical collaboration (April 2026). The company is privately held by Andreessen Horowitz, Catalio Capital Management, Bristol Myers Squibb, and a syndicate including 50Y, Allen, 8VC, NanoDimension, SV Angel, Refactor, Ulu Ventures, and Lux Capital.

Go-to-market is structured as an enterprise pharma partnership motion: high-touch business development secures multi-year research collaborations and co-development agreements, supplemented by visibility at major investor and scientific conferences (Morgan Stanley, Goldman Sachs, RBC, Canaccord Genuity, Stanford Drug Discovery Symposium, Mutational Scanning Symposium) and a science-content and apprenticeship-driven employer brand that supports talent acquisition. Pricing is not publicly disclosed; commercial value is realized through deal economics with pharma partners and future clinical-pipeline milestones rather than unit sales.

Octant Bio firmographics

Firmographics
Name
Octant Bio
Legal name
Octant, Inc.
Website
https://octant.bio
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Octant Bio is a clinical-stage biotechnology company developing the Octant Navigator—an integrated Generative Biology, Chemistry, and AI drug-discovery platform targeting protein misfolding diseases—with lead asset OCT-980 in Phase 1 for RHO-adRP retinitis pigmentosa.
Ownership category
akta.pro rank

Octant Bio industry classification

Industry
Product category
Drug Discovery Platform / Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Drug discovery platform
  • Small molecule therapeutics
  • Synthetic biology drug discovery
  • Protein misfolding correctors
  • Generative AI drug discovery

Where Octant Bio is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Octant Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Strategic pharma research collaborations: Research collaboration agreements with large pharmaceutical partners such as Bristol Myers Squibb (e.g., 2022 collaboration; November 12, 2025 collaboration to discover novel small molecules for neurodegenerative diseases). Typically involve upfront/research funding, milestone payments, and potential downstream royalties or licensing economics tied to partnered programs.
  2. Venture equity financing: Series B financing of $80M led by Catalio Capital Management in April 2022 with participation from Bristol Myers Squibb and other investors (Andreessen Horowitz, 50Y, Allen, 8VC, NanoDimension, SV Angel, Refactor, Ulu, Lux). Pre-revenue therapeutics company; primary funding mechanism to date.
  3. Non-dilutive grant funding: Targeted grant funding supporting specific programs — e.g., $4.9M grant from the Gates Foundation to launch the HPV-Driven Cancer Therapeutics Program (June 11, 2025), and ARPA-H funding for a Collaborative AI Initiative to advance drug discovery and prevent side effects (October 23, 2024).

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based / Not publicly disclosed — pre-commercial therapeutics pipeline with pharma research collaborations

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Octant Bio product offering

Product offering

Core offering

Octant Bio operates the Octant Navigator, an integrated drug-discovery platform that combines Generative Biology (RNA-barcoded mammalian synthetic biology cell sensors), Generative Chemistry (nano-scale automated synthesis), and Generative AI in a weekly Design-Build-Test-Learn cycle to engineer small molecule drugs that modulate cellular mechanisms of disease. The company applies Deep Mutational Scanning to map every amino-acid variant of target proteins and currently sells its discovery capabilities via research collaborations with pharmaceutical partners (e.g., Bristol Myers Squibb), non-dilutive grants (Gates Foundation, ARPA-H), and an internal clinical pipeline led by OCT-980 (an oral small molecule corrector for RHO-adRP retinitis pigmentosa now in Phase 1a).

Product overview

Octant Bio offers a single integrated drug-discovery platform — the Octant Navigator — composed of three interlocking modules (Generative Biology, Generative Chemistry, and Generative AI) plus platform capabilities such as Deep Mutational Scanning (DMS), HT-SAR direct-to-biology screening, and the Hypatia robotic drug hunter, that together drive iterative weekly design–build–test–learn cycles on cellular mechanisms. Internal programs include the lead clinical candidate OCT-980 (an oral small-molecule corrector for RHO-associated autosomal dominant retinitis pigmentosa, Phase 1a initiated Q1 2026), along with discovery programs in Fabry disease, undisclosed neurodegeneration, p53-mutant cancers, HPV-induced cancers (Gates Foundation collaboration), MC4R metabolism, and undisclosed targets.

Differentiator

Problem solved

Functional benefit

Brands

  • Octant Navigator: Proprietary next-generation drug discovery platform that integrates Generative Biology, Generative Chemistry, and Generative AI for design, build, test, learn iterations across chemistry and biology.

Products and services

  • Octant Navigator Next-generation drug discovery platform integrating Generative Biology, Generative Chemistry, and Generative AI in iterative design–build–test–learn loops to engineer small molecules that modulate cellular mechanisms driving disease, rather than only binding isolated target proteins.
  • OCT-980 First-in-disease oral small molecule corrector designed to correct protein misfolding caused by rhodopsin (RHO) gene mutations, the root cause of RHO-associated autosomal dominant retinitis pigmentosa (adRP). In Phase 1a clinical testing as of Q1 2026 with an integrated Phase 1/2 study planned.
  • Pharma research collaboration and co-development services Strategic research collaboration agreements with large pharmaceutical partners (notably Bristol Myers Squibb, originally announced 2022 and expanded November 12, 2025 for neurodegenerative diseases) that apply the Octant Navigator platform to discover novel small molecules, typically involving upfront/research funding, milestone payments, and potential downstream royalties or licensing economics.

Quantifiable outcome

  • Iteratively built and screened 250,000+ custom compounds direct-to-biology in the RHO-adRP program, yielding leads that rescue the most prevalent clinically-relevant rhodopsin mutations, are orally bioavailable, and cross the blood-retinal barrier.
  • +3 more outcomes

Companies that use Octant Bio

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Octant Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature7 records

Octant Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, flagship and minor.

  • Foundation Fighting BlindnesscoreStrategic or Co-development Partner · 21 April 2026Collaboration announced April 21–22, 2026 to expand the Uni-Rare Natural History Study with a new RHO cohort, supporting the OCT-980 / RHO-adRP program and broader understanding of rhodopsin mutation disease progression.
  • Bristol Myers SquibbflagshipStrategic or Co-development Partner · 12 November 2025Research collaboration announced November 12, 2025 to discover novel small molecules for neurodegenerative diseases. Builds on the original 2022 Octant–BMS drug-discovery partnership and joint work presented at Stanford Drug Discovery Symposium 2024 on a Deep Mutational Scan of TYK2.
  • Gates FoundationcoreStrategic or Co-development Partner · 11 June 2025Partner on Octant's HPV-induced cancers program (Hit ID stage in pipeline) and funder via a $4.9M grant awarded June 11, 2025 to launch the HPV-Driven Cancer Therapeutics Program.
  • Ginkgo BioworksminorStrategic or Co-development Partner · 10 December 2020Established a Bay Area coronavirus test processing facility in December 2020 leveraging Octant's SwabSeq technology; partnership was a non-pharma operational collaboration during the COVID-19 pandemic.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Octant Bio competitors and assessment

Company assessment

Direct peers

  • Insitro: Insitro is a clinical-stage AI/ML-driven drug discovery company combining induced pluripotent stem cell biology, high-throughput genetics, and machine learning to engineer small molecule and genetic medicines. Highly comparable to Octant's Navigator approach of integrating high-throughput biology, chemistry, and ML in iterative discovery loops.
  • Schrödinger: Schrödinger combines physics-based computational chemistry, ML, and a co-discovery model with pharma partners to develop small molecule therapeutics. Directly comparable to Octant's Generative Chemistry and Generative AI capabilities and its pharma-partnered business model.
  • Exscientia: Exscientia is an AI-native pharma using generative design and automated chemistry to advance small molecule candidates, with multiple clinical-stage programs and major pharma partnerships. Comparable to Octant as a direct AI/chemistry platform competitor.
  • Recursion Pharmaceuticals: Recursion operates one of the largest AI-driven biology and chemistry platforms, using high-throughput automated wet-lab experiments and ML to discover small molecules across multiple therapeutic areas with several clinical-stage assets. Directly comparable to Octant on platform model, scale, and clinical-stage status.
  • Relay Therapeutics: Relay Therapeutics combines computational methods with structural biology and chemistry to design precision medicines against validated targets, with multiple clinical-stage assets. SAB member Mark Murcko is a Relay founder and the platform emphasis on motion-based drug design overlaps with Octant's mechanism-based cellular screening.
  • Eikon Therapeutics: Eikon uses live-cell high-throughput imaging combined with AI/ML to track protein dynamics in living cells for drug discovery. Comparable to Octant on the premise of generating large-scale biological datasets with ML to discover mechanistically novel small molecules.

Broad incumbents

  • Ginkgo Bioworks: Ginkgo Bioworks operates a broad horizontal synthetic biology and cell programming platform serving applications from biomanufacturing to biosecurity (NYSE: DNA). Ginkgo CEO Jason Kelly sits on Octant's board, and the companies share an Emeryville-Bay Area cluster and synthetic biology heritage.

Emerging players

  • Atomwise: Atomwise applies deep learning to structure-based small molecule design and has multiple pharma partnerships. Comparable to Octant on AI-driven small molecule discovery but smaller scale and less integrated wet-lab automation.
  • Isomorphic Labs: Isomorphic Labs is Alphabet/DeepMind's commercial AI drug discovery entity building an integrated computational biology and chemistry platform. Comparable to Octant as an AI-native discovery platform with pharma partnerships (Novartis, Lilly) but operating at vastly greater capital scale.
  • Dewpoint Therapeutics: Dewpoint develops small molecule drugs targeting biomolecular condensates, with SAB founder Mark Murcko. Partial overlap with Octant on mechanism-based discovery and on shared scientific leadership network.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Octant Bio social profiles

Digital presence

Octant Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Octant Bio leadership team

Management profile

Number of profiles

Profiles21 records

Octant Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Octant Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Octant Bio

What does Octant Bio do?

Octant Bio operates the Octant Navigator, an integrated drug-discovery platform that combines Generative Biology (RNA-barcoded mammalian synthetic biology cell sensors), Generative Chemistry (nano-scale automated synthesis), and Generative AI in a weekly Design-Build-Test-Learn cycle to engineer small molecule drugs that modulate cellular mechanisms of disease. The company applies Deep Mutational Scanning to map every amino-acid variant of target proteins and currently sells its discovery capabilities via research collaborations with pharmaceutical partners (e.g., Bristol Myers Squibb), non-dilutive grants (Gates Foundation, ARPA-H), and an internal clinical pipeline led by OCT-980 (an oral small molecule corrector for RHO-adRP retinitis pigmentosa now in Phase 1a).

Is Octant Bio a public or private company?

Octant Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Octant Bio founded?

Octant Bio was founded in 2017. It employs 51 to 100 people.

Where is Octant Bio based?

Octant Bio is headquartered in Emeryville, United States, in the North America region.

How does Octant Bio make money?

Three revenue lines are on record. Strategic pharma research collaborations are the primary driver. The others are venture equity financing and non-dilutive grant funding.

Who are Octant Bio's main competitors?

Direct peers on record are Insitro, Schrödinger, Exscientia, Recursion Pharmaceuticals, Relay Therapeutics and Eikon Therapeutics. Ginkgo Bioworks is listed as a broad incumbent. Emerging players are Atomwise, Isomorphic Labs and Dewpoint Therapeutics.

Does Octant Bio have an API?

No public API is recorded for Octant Bio.

What industry is Octant Bio in?

Octant Bio's product category is Drug Discovery Platform / Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyFDA grants orphan drug status to Octant's OCT-980 for RPThe FDA granted orphan drug designation to Octant's OCT-980 for rhodopsin-associated autosomal dominant retinitis pigmentosa. The designation offers seven years of US market exclusivity and tax credits. The therapy is in a Phase I/II study, with clinical data needed to establish it as an oral disease-modifying option.BioSpaceOctant Announces First Patient Dosed in Phase 1b/2 Clinical Study of OCT-980 for the Treatment of Retinitis PigmentosaOctant announced the first patient has been dosed in its Phase 1b/2 clinical study of OCT-980, an oral small molecule for rhodopsin-associated autosomal dominant retinitis pigmentosa. The study evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy, with no approved treatments for this disease.Timmerman ReportSmall Molecules To Correct Disease: Sri Kosuri on The Long RunSri Kosuri, co-founder and CEO of Octant Bio, discussed the company's development of oral small molecule drugs designed to correct protein misfolding associated with rare diseases, cancers, and metabolic disorders. Octant’s lead candidate, targeting rhodopsin-associated autosomal dominant Retinitis Pigmentosa, entered its first clinical trial in March to potentially halt disease progression and improve low-light vision.NatureMapping the avoid-ome: a systematic open-science approach to predictive ADMETThe OpenADMET consortium, comprising UCSF, Octant, and the Open Molecular Software Foundation, has launched an open-science initiative to address critical data gaps in ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction for small molecule drug discovery. Funded by ARPA-H and the Gates Foundation, the project aims to generate pre-competitive, high-quality datasets on the "Avoid-ome"—specific proteins that cause drug liabilities—to improve machine learning models and accelerate safe drug development.CoinTelegraphTor Project Launches Web3 Campaign for Internet FreedomThe Tor Project launched a Web3 crowdfunding campaign on May 19 to support 10 nonprofit projects for internet freedom, accepting crypto contributions. An initial $115,000 matching pool amplifies donations via quadratic funding, and the campaign comes amid global internet freedom decline over 15 years.GlobeNewswireZymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery PlatformZymergen expanded its agreement with Octant to scale its next-generation drug discovery platform. Octant purchased six additional Reconfigurable Automation Carts, more than doubling its initial investment. The expansion aims to increase throughput and capabilities for complex workflows.GlobeNewswireZymergen Sells Modular Automation System to Octant to Scale Next-Generation Drug Discovery PlatformZymergen agreed to sell a modular automation system to Octant to scale its drug discovery platform. The initial installation includes 5 Reconfigurable Automation Carts, with expansion planned as workflows grow. Additional terms were not disclosed.Pulse 2.0Therapeutics Company Octant Secures $80 Million In Series B FundingOctant raised $80 million in Series B funding led by Catalio Capital Management, with participation from Bristol Myers Squibb and existing investors. The company also announced a Deep Mutational Scanning partnership with Bristol Myers Squibb and appointed Dean Artis as Chief Scientific Officer. Proceeds will expand its platform and pipeline, including small molecule chaperone therapies for rare genetic diseases.FinSMEsOctant Raises $80M in Series B Funding RoundEmeryville, California-based data-driven therapeutics company Octant raised $80 million in a Series B round led by Catalio Capital Management, with participation from Bristol Myers Squibb, Andreessen Horowitz Bio Fund, Allen & Co. and 50 Years VC. The company, which has raised $115 million total, will use the funds to expand its platform, pipeline and proprietary drug discovery technology. Octant also announced a collaboration with Bristol Myers Squibb targeting inflammation-related pathways.VC News DailyOctant Secures $80M Series B Financing RoundOctant, a data-driven therapeutics company, announced an $80 million Series B financing round led by Catalio Capital Management, with participation from Bristol Myers Squibb and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC. As part of the round, Octant also established a Deep Mutational Scanning biopharma partnership with Bristol Myers Squibb and appointed Dean Artis as Chief Scientific Officer and Feng Zhang to its Scientific Advisory Board.